Status:
TERMINATED
A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Fibromyalgia
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate if DVS SR is safe and effective in the treatment of pain associated with fibromyalgia syndrome, and if so to identify the efficacious doses.
Eligibility Criteria
Inclusion
- \- Fibromyalgia diagnosed according to 1990 American College of Rheumatology criteria
Exclusion
- Unstable medical or psychological conditions that would compromise the subject's safety or put the subject at greater risk during study participation
- Other painful conditions that may confound the diagnosis or assessment of fibromyalgia
- Treatment with other drugs for fibromyalgia with 14 days of study start or during the study
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT00696787
Start Date
June 1 2008
End Date
January 1 2009
Last Update
February 25 2013
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntsville, Alabama, United States, 35801
2
Roseville, California, United States, 95661
3
San Diego, California, United States, 92108
4
San Diego, California, United States, 92128